hers plan to search for such drug
targets. They will also search for subtle genetic differences among
patients in the response-related genes in search of inherited genetic
differences that might explain gene expression and methotrexate response.
Finally, the researchers will explore whether patients who respond poorly
to methotrexate have specific gene deletions or other genetic alterations
in their leukemia cells that cause such poor response.
The findings broadly confirm the value of such sweeping surveys of gene
expression in understanding response to anti-cancer drugs.
"Studies such as these add another piece of evidence that this
genome-wide approach is very insightful and helpful and informative," Evans
said. "If you simply look for the genes that you think might be important,
you are likely to miss a number of genes that are."
Other authors include Deqing Pei, Wenjian Yang, Cheng Cheng, Ching-Hon
Pui, Mary Relling, John Panetta and Meyling Cheok (St. Jude); Michael J.
Sorich (University of South Australia); Nicolas Pottier (Pole Recherche,
France); Leo Kager (St. Anna Children's Hospital, Austria); and Gabriele
Stocco (University of Trieste, Italy).
This work was supported by National Institutes of Health grants, a
Cancer Center Support Grant, a FM Kirby Clinical Research Professorship
from the American Cancer Society and ALSAC.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for
its pioneering work in finding cures and saving children with cancer and
other catastrophic diseases. Founded by late entertainer Danny Thomas and
based in Memphis, Tenn., St. Jude freely shares its discoveries with
scientific and medical communities around the world. No family ever pays
for treatments not covered by insurance, and families without insurance are
never asked to pay. St. Jude is financially supported by ALSAC, its
fundraising organization. For more information,
Page: 1 2 3 4 Related medicine technology :1
|SOURCE St. Jude Children's Research Hospital|
Copyright©2008 PR Newswire.
All rights reserved
. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia2
. Cardiac Safety Study of Stinger S-200 Published3
. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients4
. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model5
. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling6
. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study7
. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine8
. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies9
. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women10
. Study Shows Intradigms RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models11
. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months